Topic: domestic vaccine manufacturing capacity

The Short Report – March 31, 2021: Canadian government invests $925 million in biomanufacturing, funding for variants research, a new digitalization centre, and more

Ottawa announces major funding to expand Sanofi Pasteur’s Ontario facility for domestic biomanufacturing and vaccine preparedness; there’s new funding support for COVID-19 variants research and a new national network, and Siemens launches its first centre to accelerate the digitalization of energy and infrastructure in Canada.

Calgary vaccine developer reaches deal with Manitoba government after hearing no response from Ottawa

Providence Therapeutics, a Calgary biotechnology company in human trials with its COVID-19 vaccine, struck a supply deal with the Government of Manitoba after sending the federal government a proposal and receiving no response. In a video, Providence founder and CEO Brad Sorenson criticized Ottawa’s “apathetic response” as “unacceptable” and he implored the government to take initiative to establish a secure domestic vaccine supply.

NGen joins $10-million effort to bolster manufacturing capacity for a COVID-19 vaccine

The NGen supercluster has awarded $27 million in funding for 12 advanced manufacturing projects that can supply critical health care products to combat COVID-19. The funding includes $5 million for Providence Therapeutics and partner Northern RNA to establish manufacturing capacity in Calgary for Providence’s made-in-Canada vaccine.